Markets · 1 sources covering this

Moderna shares climb over 110% as mRNA vaccine with Merck succeeds in large trial for skin cancer

The study is still ongoing, but interim results showed that the treatment, Intismeran, met its primary endpoint of reducing the risk of cancer recurrence

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

MintLean R·1h ago
Moderna shares climb over 110% as mRNA vaccine with Merck succeeds in large trial for skin cancer
The study is still ongoing, but interim results showed that the treatment, Intismeran, met its primary endpoint of reducing the risk of cancer recurrence
Read at Mint →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/e7927677f959232aeade79e9094e05cbb8e431d3"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Moderna shares climb over 110% as mRNA vaccine with Merck succeeds in large trial for skin cancer"></iframe>

Moderna shares climb over 110% as mRNA vaccine with Merck succeeds in large trial for skin cancer

How 1 sources are covering this

Moderna shares climb over 110% as mRNA vaccine with Merck succeeds in large trial for skin cancer

More from Markets

Metal stock to be in focus on Thursday after this Capex expansion update. Details here

US stocks bounce back as bond yields retreat

Rs 3 crore to Rs 4,925 crore: Sebi order gives details on Dhenu Buildcon market cap surge

SanDisk shares soar 3,400% in one year. Can the rally sustain its momentum?

Reader

Trust & legal

Across the network